370 related articles for article (PubMed ID: 9400001)
41. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors.
Seeman P; Corbett R; Van Tol HH
Neuropsychopharmacology; 1997 Feb; 16(2):93-110; discussion 111-35. PubMed ID: 9015795
[TBL] [Abstract][Full Text] [Related]
42. In the search for a novel class of antipsychotic drugs: preclinical pharmacology of FG5803, a 1-piperazinecarboxamide derivative.
Björk A; Christensson E; Albinsson A; Gustafsson B; Pettersson E; Pettersson G; Svartengren J; Andersson G
J Pharmacol Exp Ther; 1994 Dec; 271(3):1338-47. PubMed ID: 7996444
[TBL] [Abstract][Full Text] [Related]
43. Effects of yohimbine on dopamine dependent behaviours in rats and mice.
Bende MM; Bapat TR; Balsara JJ; Chandorkar AG
Indian J Physiol Pharmacol; 1990 Jul; 34(3):195-200. PubMed ID: 2286423
[TBL] [Abstract][Full Text] [Related]
44. The dopamine D4 receptor antagonist L-745,870: effects in rats discriminating cocaine from saline.
Costanza RM; Terry P
Eur J Pharmacol; 1998 Mar; 345(2):129-32. PubMed ID: 9600627
[TBL] [Abstract][Full Text] [Related]
45. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.
Iorio LC; Barnett A; Leitz FH; Houser VP; Korduba CA
J Pharmacol Exp Ther; 1983 Aug; 226(2):462-8. PubMed ID: 6135795
[TBL] [Abstract][Full Text] [Related]
46. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
Janssen PA; Awouters FH
Arzneimittelforschung; 1994 Mar; 44(3):269-77. PubMed ID: 7514873
[TBL] [Abstract][Full Text] [Related]
47. Mechanism of action of clozapine-induced modification of motor behavior in an animal model of the "super-off" phenomenon.
Dziewczapolski G; Menalled LB; Savino MT; Mora M; Stefano FJ; Gershanik O
Mov Disord; 1997 Mar; 12(2):159-66. PubMed ID: 9087973
[TBL] [Abstract][Full Text] [Related]
48. Behavioral disinhibition and depression in amphetaminized rats: a comparison of risperidone, ocaperidone and haloperidol.
Megens AA; Niemegeers CJ; Awouters FH
J Pharmacol Exp Ther; 1992 Jan; 260(1):160-7. PubMed ID: 1370539
[TBL] [Abstract][Full Text] [Related]
49. Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.
Hrib NJ; Jurcak JG; Bregna DE; Burgher KL; Hartman HB; Kafka S; Kerman LL; Kongsamut S; Roehr JE; Szewczak MR; Woods-Kettelberger AT; Corbett R
J Med Chem; 1996 Sep; 39(20):4044-57. PubMed ID: 8831770
[TBL] [Abstract][Full Text] [Related]
50. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
Ogren SO; Hall H; Köhler C; Magnusson O; Florvall L
Arzneimittelforschung; 1985; 35(8):1227-31. PubMed ID: 2866774
[TBL] [Abstract][Full Text] [Related]
51. Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane .
Bymaster FP; Shannon HE; Rasmussen K; Delapp NW; Mitch CH; Ward JS; Calligaro DO; Ludvigsen TS; Sheardown MJ; Olesen PH; Swedberg MD; Sauerberg P; Fink-Jensen A
Eur J Pharmacol; 1998 Sep; 356(2-3):109-19. PubMed ID: 9774240
[TBL] [Abstract][Full Text] [Related]
52. [The possible neurochemical mechanisms of the neuroleptic action of buspirone-like serotonin agonists].
Kharin NA; Dolzhenko AT; Titievskiĭ AV; Naletov SV
Eksp Klin Farmakol; 1993; 56(4):12-4. PubMed ID: 8106056
[TBL] [Abstract][Full Text] [Related]
53. (S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist.
TenBrink RE; Bergh CL; Duncan JN; Harris DW; Huff RM; Lahti RA; Lawson CF; Lutzke BS; Martin IJ; Rees SA; Schlachter SK; Sih JC; Smith MW
J Med Chem; 1996 Jun; 39(13):2435-7. PubMed ID: 8691438
[No Abstract] [Full Text] [Related]
54. gamma-Hydroxybutyrate ligands possess antidopaminergic and neuroleptic-like activities.
Hechler V; Peter P; Gobaille S; Bourguignon JJ; Schmitt M; Ehrhardt JD; Mark J; Maitre M
J Pharmacol Exp Ther; 1993 Mar; 264(3):1406-14. PubMed ID: 8095552
[TBL] [Abstract][Full Text] [Related]
55. Synthesis and atypical antipsychotic profile of some 2-(2-piperidinoethyl)benzocycloalkanones as analogues of butyrophenone.
Fontenla JA; Osuna J; Rosa E; Castro ME; G-Ferreiro T; Loza-García I; Calleja JM; Sanz F; Rodríguez J; Raviña E
J Med Chem; 1994 Aug; 37(16):2564-73. PubMed ID: 7914540
[TBL] [Abstract][Full Text] [Related]
56. Behavioral, anti-dopaminergic, and prohypnotic effects of neuroleptics during and after prolonged treatment.
Biazzi A; Fregnan GB
Adv Biochem Psychopharmacol; 1980; 24():351-7. PubMed ID: 6105785
[No Abstract] [Full Text] [Related]
57. 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics.
Bolós J; Gubert S; Anglada L; Planas JM; Burgarolas C; Castelló JM; Sacristán A; Ortiz JA
J Med Chem; 1996 Jul; 39(15):2962-70. PubMed ID: 8709130
[TBL] [Abstract][Full Text] [Related]
58. Behavioural correlates to the dopamine D-1 and D-2 antagonists.
Christensen AV; Arnt J; Hyttel J; Svendsen O
Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830
[TBL] [Abstract][Full Text] [Related]
59. Behavioral characterization of the new potent nonselective dopamine agonist pergolide.
Helton DR; Modlin DL; Williams PD
Arzneimittelforschung; 1992 Jul; 42(7):885-90. PubMed ID: 1418051
[TBL] [Abstract][Full Text] [Related]
60. 3-[[(4-Aryl-1-piperazinyl)alkyl]cyclohexyl]-1H-indoles as dopamine D2 partial agonists and autoreceptor agonists.
Wustrow DJ; Smith WJ; Corbin AE; Davis MD; Georgic LM; Pugsley TA; Whetzel SZ; Heffner TG; Wise LD
J Med Chem; 1997 Jan; 40(2):250-9. PubMed ID: 9003524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
